Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice

Stem Cells
H AkahoriH Miyazaki

Abstract

Thrombopoietin, the endogenous c-Mpl ligand, is a novel lineage-specific hematopoietic factor that plays a pivotal role in the regulation of megakaryocytopoiesis and thrombopoiesis. In this study, we examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule of recombinant human c-Mpl ligand derivatized with polyethylene glycol, on myelosuppressive chemotherapy-induced thrombocytopenia in mice. We developed a new murine model of thrombocytopenia induced by i.v. injections of mitomycin C (MMC) for two consecutive days. In control mice, platelet counts began to decrease on day 6, reached a nadir of less than 5% of basal level on day 14, and could not recover to basal level by day 26. Administration of PEG-rHuMGDF greatly enhanced recovery of the number of megakaryocyte progenitor cells and the megakaryocytes in bone marrow, and markedly reduced the severity of thrombocytopenia; it also accelerated platelet recovery in a dose-dependent manner in myelosuppressed mice. Mice receiving consecutive administration of higher doses of PEG-rHuMGDF showed no thrombocytopenia but rather had platelet counts being increased over basal level. Although absolute neutrophil c...Continue Reading

References

Jul 1, 1992·British Journal of Haematology·B GodeauP Bierling
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·K KaushanskyC Lofton-Day
Jun 9, 1995·Gene·K OgamiH Miyazaki
Jul 1, 1995·Journal of Biochemistry·T KatoE Maeda

❮ Previous
Next ❯

Citations

Oct 10, 1998·Stem Cells·T KatoH Miyazaki
Sep 30, 2000·Stem Cells·T KatoH Miyazaki
May 7, 1998·Transfusion Science·L A Harker
May 5, 1999·Current Opinion in Hematology·L A Harker
May 5, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·H AkahoriH Miyazaki
Jan 28, 1999·Leukemia Research·E Archimbaud, X Thomas
Mar 26, 2011·Annals of the New York Academy of Sciences·Graham Molineux
Oct 15, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jane L LiesveldYuhchyau Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.